IFIN Stock Forecast 2025-2026
Distance to IFIN Price Targets
IFIN Price Momentum
🤔 Considering InFinT (IFIN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest IFIN Stock Price Targets & Analyst Predictions
IFIN has shown a year-to-date change of 29.3% and a 1-year change of -82.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for IFIN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IFIN Analyst Ratings
IFIN Price Target Range
Latest IFIN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IFIN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Cure Pharmaceutical Holding Corp. (IFIN) Competitors
The following stocks are similar to InFinT based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cure Pharmaceutical Holding Corp. (IFIN) Financial Data
Cure Pharmaceutical Holding Corp. has a market capitalization of $66.42M with a P/E ratio of 36.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +4.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cure Pharmaceutical Holding Corp. (IFIN) Business Model
About Cure Pharmaceutical Holding Corp.
Develops innovative drug delivery systems.
The company generates revenue through the development and commercialization of advanced drug delivery technologies, such as oral thin films and transdermal systems. By enhancing the bioavailability and efficacy of pharmaceutical compounds, it partners with other pharmaceutical firms to create tailored drug formulations that meet specific medical needs.
Cure Pharmaceutical operates in key therapeutic areas like pain management, oncology, and central nervous system disorders. Its focus on personalized medicine and strategic industry partnerships positions it to address significant unmet medical needs and expand delivery options in the healthcare market.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Alexander Edgarov
Country
United States
IPO Year
2022
Website
www.infintspac.comCure Pharmaceutical Holding Corp. (IFIN) Latest News & Analysis
Seamless Group Inc. and INFINT Acquisition Corp. have completed their business combination. CURRENC Group Inc. will begin trading on Nasdaq under the ticker "CURR" on September 3, 2024.
The launch of CURRENC Group Inc. on Nasdaq under ticker "CURR" signals a new investment opportunity and potential growth in the fintech sector following its merger with INFINT.
INFINT Acquisition Corporation plans to voluntarily delist its units and Class A shares from the NYSE, pending the completion of its business combination with Seamless Group Inc.
Delisting from the NYSE may impact liquidity and trading volume of INFINT’s shares, affecting investor sentiment and valuation post-business combination with Seamless.
INFINT Acquisition Corp. plans to voluntarily delist its units and Class A shares from NYSE American, pending the completion of its business combination with Seamless Group Inc.
Delisting from NYSE American may signal reduced market visibility and liquidity for INFINT, impacting investor confidence and potential valuation post-business combination with Seamless.
INFINT Acquisition Corp. received a notice from NYSE for not having the required 300 public shareholders. It has 45 days to submit a plan to regain compliance within 18 months.
INFINT Acquisition Corporation's potential delisting due to inadequate public shareholders may impact its stock price and investor confidence, signaling heightened risk and uncertainty.
INFINT Acquisition Corporation (NYSE: IFIN) will hold an extraordinary shareholder meeting on August 18, 2023, to vote on extending its business combination deadline to February 23, 2024.
The proposed extension allows INFINT to delay its business combination, potentially increasing the chance of securing a favorable deal, which could impact stock performance and investor confidence.
INFINT Acquisition Corporation (NYSE: IFIN) has canceled its extraordinary general meeting set for November 22, 2022, and will withdraw proposals from its November 2, 2022 proxy statement.
The cancellation of the extraordinary general meeting may signal uncertainty or strategic shifts within INFINT Acquisition Corporation, potentially impacting shareholder confidence and stock performance.
Frequently Asked Questions About IFIN Stock
What is Cure Pharmaceutical Holding Corp.'s (IFIN) stock forecast for 2025?
Analyst forecasts for Cure Pharmaceutical Holding Corp. (IFIN) are not currently available. The stock is trading at $2.03.
Is IFIN stock a good investment in 2025?
Analyst ratings for IFIN are not currently available. The stock is currently trading at $2.03. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IFIN stock?
Price predictions from Wall Street analysts for IFIN are not currently available. The stock is trading at $2.03.
What is Cure Pharmaceutical Holding Corp.'s business model?
The company generates revenue through the development and commercialization of advanced drug delivery technologies, such as oral thin films and transdermal systems. By enhancing the bioavailability and efficacy of pharmaceutical compounds, it partners with other pharmaceutical firms to create tailored drug formulations that meet specific medical needs.
What is the highest forecasted price for IFIN Cure Pharmaceutical Holding Corp.?
Price targets from Wall Street analysts for IFIN are not currently available. The stock is trading at $2.03.
What is the lowest forecasted price for IFIN Cure Pharmaceutical Holding Corp.?
Price targets from Wall Street analysts for IFIN are not currently available. The stock is trading at $2.03.
What is the overall IFIN consensus from analysts for Cure Pharmaceutical Holding Corp.?
Analyst ratings for IFIN are not currently available. The stock is trading at $2.03.
How accurate are IFIN stock price projections?
Stock price projections, including those for Cure Pharmaceutical Holding Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
